Polymyxin B nonapeptide, derived by cleavage of the fatty acyl diaminobutyric acid from polymyxin B, is considerably less toxic, lacks bactericidal activity, and retains its ability to render gram-negative bacteria susceptible to several antibiotics by permeabilizing their outer membranes. The peptide rendered all 53 polymyxin-susceptible strains tested more susceptible to novobiocin, lowering the MIC of novobiocin eightfold or more. The combination of polymyxin B nonapeptide with novobiocin or with erythromycin administered intraperitoneally in multiple doses synergistically protected mice infected with gram-negative bacteria. This combination may be clinically useful because of the apparent rarity of the acquisition of resistance.
Resistance to hydrophobic antibiotics in gram-negative bacteria may be either due to a decrease in the penetration of the antibiotic through the outer membrane or due to specific mechanisms, such as gene mutation or acquisition of resistance genes. The distinction between the two types of resistance is important, because it allows the search for antibiotics to which the development of specific mechanisms of resistance are rare but to which the bacterial membrane is impermeable. Such active but nonpenetrating antibiotics may gain clinical use when combined with membrane-active agents that increase their penetration. Polycations at sublethal concentrations increase the permeability of the outer membranes of gramnegative bacteria and render these microorganisms susceptible to many hydrophobic antibiotics (15) (16) (17) (18) . Among the various polycations tested, polymyxin B nonapeptide (PMBN), derived by cleaving the fatty acid moiety from polymyxin B, has been studied the most. PMBN lacks antibacterial activity but renders most polymyxin-susceptible gram-negative bacteria susceptible to hydrophobic antibiotics by disorganizing the bacterial outer membranes to enhance antibiotic penetration (17) (18) (19) . In the present study, we sought to further determine the incidence of strains that exhibit permeability-associated resistance in assays with PMBN and to examine the therapeutic efficacy of hydrophobic antibiotics in combination with PMBN in experimental gram-negative infections in mice.
All clinical isolates were obtained from various body sites at regional outpatient clinics (see Table 2 ). The bacteria were grown on agar slants (nutrient agar; Difco Laboratories, Detroit, Mich.) and kept at 4°C for up to 2 weeks. The MICs of each antibiotic were determined as described elsewhere (7) .
In brief, 10 (1) harvested from the logarithmic phase of growth in nutrient broth (Difco) at 37°C or 1 x 108 CFU of Pseudomonas aeruginosa 33347 (kindly provided by Nehama Garber, Bar-Ilan University, Ramat-Gan, Israel) harvested from agar slants after overnight growth at 37°C (8) .
The efficacy of PMBN either alone or in combination with other antibiotics was evaluated following intraperitoneal administration of 0.5 ml of water containing various amounts of the antibiotics to groups of 6 to 20 mice at the desired time intervals after bacterial challenge. The number of dead mice was counted 1 week later. The 50% lethal doses of the bacteria in mice were determined as described previously (10) to be 2 x 105 and 5 x 107 CFU for K pneumoniae and P. aeruginosa, respectively.
PMBN rendered all polymyxin-susceptible strains susceptible to six different antibiotics tested, except for one P. aeruginosa strain resistant to nafcillin and one Escherichia coli and two K pneumoniae strains resistant to vancomycin (Table 1) . These resistant strains probably possess mechanisms of resistance unrelated to permeability. This presumption is strengthened by the inability of the deacylated peptide to lower the MIC of ampicillin against three penicillinase-producing strains.
Further studies focused on the ability of PMBN to reduce the MIC of novobiocin for 55 clinical isolates belonging to nine bacterial species and exhibiting multiple resistance patterns. PMBN caused a significant reduction in the MIC of novobiocin for all 53 polymyxin-susceptible strains tested, including 7 quinolone-resistant strains ( Table 2 ). The MIC of norfloxacin for six quinolone-resistant strains was 600 ptg/ml, and PMBN did not cause a significant reduction in this MIC (data not shown), suggesting that resistance to quinolones is probably due to mechanisms other than permeability. We conclude that resistance to novobiocin in gram-negative bacteria is probably solely due to the inability of the antibiotic to penetrate the outer membrane. In a separate study, we found that 30 ,ug of PMBN per ml reduced the MIC of novobiocin for P. aeruginosa (blood isolate) from 250 to 0.05 and 0.1 ,ug/ml in the presence of 10 and 5% normal human serum, respectively.
Previous studies showed that a single intravenous adminis-NOTES a All isolates were resistant to >350 p.g of PMBN per ml. PMBN was prepared by hydrolysis with ficin as described previously (5, 18) . PMBN was added at 30 ,ug/ml, except for Pseudomonas strains, for which it was added at 7.5 jig/ml.
b The sources of the isolates were as follows: Acinetobacter spp., six from urine and one from a wound; E. coli, four from departmental stock, eight from urine, and two from wounds; Enterobacter spp., four from blood, one from a wound, and one from sputum; K pneumoniae, five from urine, three from sputum, and two from wounds; P. mirabilis, two from urine; P. aeruginosa, nine from urine, three from wounds, two from sputum, and one from blood; and S. typhimurium, one from departmental stock. With the exception of the two P. mirabilis isolates, all isolates were susceptible to polymyxin B. The antibiotic susceptibilities of the isolates were tested with Sensi-Discs (Becton Dickinson and Co., Rutherford, N.J.) according to the manufacturer's instructions as described elsewhere (2) and according to the guidelines of the National Committee for Clinical Laboratory Standards for classifying isolates as susceptible or resistant (12). All isolates were resistant to clindamycin, erythromycin, nafcillin, rifampin, and vancomycin. A total of 5 isolates of Acinetobacter spp. and 2 isolates of P. aeruginosa were resistant to at least three of the antibiotics listed below, 13 were resistant to only two, and 6 were resistant to none: ampicillin, chloramphenicol, cefotaxime, carbenicillin, gentamicin, kanamycin, nalidixic acid, norfloxacin, streptomycin, tetracycline, and tobramycin. 50%, MIC for 50% of isolates tested. Table 1 , footnote a).
b NT, not tested.
c The amounts indicated were administered twice on day 1 after challenge.
tration of PMBN (200 mg/kg of body weight) in combination with erythromycin to mice shortly after a challenge with a lethal dose of P. aeruginosa or E. coli failed to protect the animals (11). We used P. aeruginosa and K pneumoniae strains which were resistant to >1,000 ,ug of novobiocin per ml and >200 ,ug of erythromycin per ml, respectively. The addition of PMBN to the medium rendered the strains susceptible to <32 [xg of these hydrophobic antibiotics per ml. Untreated mice challenged with P. aeruginosa developed septicemia and died within 24 to 48 hours; untreated mice died 3 to 6 days after challenge with K pneumoniae. A single intraperitoneal PMBN dose in combination with either erythromycin or novobiocin did not protect mice challenged with K pneumoniae or P. aeruginosa (Table 3 ). In contrast, multiple doses administered over two or more consecutive days protected all mice challenged with P. aeruginosa and afforded partial, albeit significant, protection to mice challenged with K pneumoniae. Our studies suggest that the combination of PMBN and novobiocin should be considered for clinical use against gramnegative infections because (i) although PMBN activity is restricted only to polymyxin-susceptible strains (11, 16) , natural resistance to polymyxins is limited to only a few gramnegative bacterial species and acquired resistance is rare (14) ; (ii) acquired specific resistance to novobiocin in gram-negative bacteria has not been reported (3) , and once the outer membrane becomes permeable, novobiocin resistance is not anticipated; (iii) PMBN is highly active in vitro and renders gram-negative bacteria susceptible to hydrophobic antibiotics at concentrations as low as 1 ,ug/ml (19) , even against strains exhibiting multiple resistance patterns; (iv) the combination of PMBN with novobiocin (or other hydrophobic antibiotics), when administered in multiple doses, protects mice challenged with a lethal dose of gram-negative bacteria; and (v) while the 50% lethal dose of polymyxin B or colistin in mice is in the range of 6 to 10 mg/kg, colistin nonapeptide is 15 times less toxic than the parent molecule (4), and doses as high as 200 mg of PMBN per kg are not lethal (11) . Furthermore, 3 mg of PMBN per kg administered intravenously to dogs and rats over a long period of time does not cause a neuromuscular blockade or neurotoxic or nephrotoxic effects, all of which have been observed in animals administered the same dose of polymyxin B (6) . Both novobiocin and polymyxins have been restricted for clinical use because of their high toxicity and because virtually all gram-negative strains are resistant to novobiocin (3) . In view of our results, these restrictions should be reconsidered, as the combination of polymyxin B nonapeptide and novobiocin at relatively low concentrations is active in vitro, affords clinical protection to lethally infected mice, and is devoid of severe toxicity; most importantly, the development of resistance to this combination is rare.
